Sangamo Therapeutics (SGMO) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

SGMO Sangamo Therapeutics

Watchlist

2.470
+0.160+6.93%

Close Dec 20 16:00 ET

2.480
+0.010+0.40%

Post 20:01 ET

515.36MMarket Cap-3.48P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Sector Update: Health Care Stocks Mixed Premarket Thursday
MT NewswiresDec 19 09:10 ET
Sangamo Shares Rally Premarket on License Deal With Astellas
WSJDec 19 06:20 ET
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
BenzingaDec 19 06:15 ET
Biggest Stock Movers Thursday: MU, MESO, and More
Seeking AlphaDec 19 05:00 ET
Trending Stocks Today | Currenc Group Shoots up 168% Pre-Market
Moomoo NewsDec 19 04:25 ET
Express News | Sangamo Therapeutics Inc - Eligible for up to $1.3 Billion in Milestone Payments
ReutersDec 19 02:30 ET

Comments

BigAlMoney

Yesterday 06:48

Fabry deal still in the works

$Sangamo Therapeutics (SGMO.US)$
Should be interesting to see what we get in up front. It's been given Accelerated Approval by FDA so BLA will be filed next year sometime once we get final patient data. I'm guessing 100 to 200 million up front.

Teddy123

Yesterday 05:03

Hello. How about u aim for that $10 target

$Sangamo Therapeutics (SGMO.US)$

Wekang

Dec 20 01:50

$Sangamo Therapeutics (SGMO.US)$ lets see how it goes. W pattern maybe.

Toninho Sandro

Dec 20 00:57

$Sangamo Therapeutics (SGMO.US)$ net outflow, rid off weak holders, yet price holding up well. in the watch list for dip picking.

Teddy123

Dec 19 12:39

Positive biotech research insights

$Sangamo Therapeutics (SGMO.US)$
The STAC-BBB capsid technology addresses one of gene therapy's most challenging obstacles - crossing the blood-brain barrier efficiently. Traditional AAV vectors struggle with CNS penetration, often requiring invasive direct administration. An effective IV-delivered solution could revolutionize neurological gene therapy by enabling broader distribution and simplified administration.
The non-human primate data showing potent BBB ...